TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A study of 29 healthy adults found that a treatment combining temporary blood-pressure-lowering medication with whole-body vibration was associated with increased levels of brain-derived proteins in the blood and changes in brain fluid flow. The researchers say the results suggest enhanced protein clearance, but the study did not test whether the approach prevents dementia or benefits people with memory problems.
Researchers in Finland report that a treatment combining temporary blood-pressure-lowering medication with rhythmic whole-body vibration was associated with increased movement of dementia-linked proteins from the brains of 29 healthy adults. The study, published November 3 in Nature Communications, offers early evidence that brain fluid-clearance processes can be influenced while participants are awake, but it does not show that the treatment prevents dementia or improves memory.
The University of Oulu and Oulu University Hospital researchers examined the treatment using multimodal MRI, physiological measurements and blood-based biomarkers. After treatment, levels in participants’ blood of several soluble proteins originating in the brain increased, including beta-amyloid 40, beta-amyloid 42 and GFAP. MRI measurements also showed changes in fluid flow and in areas around large veins in the brain.
The authors interpret those findings as evidence consistent with increased clearance of brain-derived proteins. “The results suggest that harmful proteins were cleared from the brain more efficiently than usual,” lead researcher Johanna Tuunanen, a doctoral researcher at the University of Oulu, said, according to the report. The measurements do not, by themselves, establish how much protein was removed or whether the change produces a health benefit.
The treatment used medication to temporarily lower blood pressure alongside rhythmic whole-body vibration intended to stimulate Piezo1 channels in blood vessels. The researchers say the medication strengthened slow brain pulsations associated with fluid movement. They describe the combined approach as “vasomechanical” treatment; the study’s reported findings concern short-term biological measurements, not long-term clinical outcomes.
Testing Brain Clearance While Awake
Alzheimer’s disease and other forms of dementia are associated with the gradual accumulation of proteins in the brain. The researchers are investigating whether the brain’s own waste-clearance processes could eventually offer a route to early intervention, particularly before proteins form deposits in tissue. The study provides a human test of that idea, building on earlier work in animals and observations of changes in brain fluid circulation during sleep.
For readers, the distinction between a biological signal and a proven treatment is important. An increase in soluble brain-derived proteins in the bloodstream may indicate that proteins have moved out of the brain, as the researchers propose. It does not show that participants had less brain damage, reduced dementia risk, or improved cognitive function. The findings are an early research result, not evidence that people should seek this treatment.
Professor Vesa Kiviniemi, who leads the University of Oulu’s Functional Neuroimaging Research Group, said the work could open a research avenue for studying the clearance system in relation to diagnosis, prevention and treatment. Those are potential future applications described by the researchers; none was tested as an outcome in this study.
Products Worth Considering
Withings BPM Connect Wi-Fi and Bluetooth Blood Pressure Monitor
Levoit Vital 100S-P Air Purifier for Home and Pets
LEVOIT Air Purifier for Home, Pets, Bedroom, Smart WiFi
As an affiliate, we earn on qualifying purchases.
From Sleep Biology to Human Testing
The study draws on the observation that brain-clearance activity is most active during sleep. As people fall asleep, blood pressure generally drops and slow blood-vessel and respiratory pulsations become stronger. These changes are thought to help move cerebrospinal fluid through brain tissue and carry waste products away.
Previous animal studies had suggested that temporarily lowering blood pressure could increase clearance of cerebrospinal fluid and the molecules it carries. Other animal research linked activation of Piezo1, a mechanically sensitive channel in blood vessels, with changes in lymphatic flow around the brain and reduced beta-amyloid burden. The Finnish team combined these lines of research in a study of healthy adult volunteers, rather than patients with dementia or early memory impairment.
The report says wearable, MRI-compatible equipment incorporating fNIRS and dcEEG was used alongside scanning to assess cerebrospinal fluid circulation. The results were published in Nature Communications as “Vasomechanic treatment is associated with increased efflux of human brain proteins.” The wording “associated with” reflects the reported evidence and does not establish that the treatment will prevent disease.
Clinical Benefits Remain Untested
The study involved 29 healthy adults, and the reported outcomes were short-term changes in biomarkers and imaging measures. It is not clear from the source report how long those changes lasted, whether repeated treatment would produce the same response, or whether the findings apply to older adults or people with cognitive impairment.
The results also do not establish that the treatment reduces protein deposits, slows disease progression, improves cognition or is safe and effective for routine use. Increased levels of proteins in blood were interpreted as consistent with efflux from the brain, but the report does not provide a clinical measure of dementia risk or patient benefit. Further studies are needed to test those questions.
Researchers Plan Patient Follow-Up
Kiviniemi said the next step is to investigate whether the treatment offers benefits to people with early-stage memory impairment. The team is planning follow-up studies in collaboration with other experts, according to the report. Details such as the study design, participant numbers and schedule have not yet been provided.
Those studies would need to determine whether the observed changes can be reproduced and whether they correspond to meaningful outcomes for patients. Until then, the current findings should be understood as preliminary evidence about brain-fluid dynamics and protein movement in healthy volunteers, not as a demonstrated dementia treatment.
Key Questions
What treatment did the researchers test?
They combined medication that temporarily lowers blood pressure with rhythmic whole-body vibration intended to stimulate Piezo1 channels in blood vessels.
What changed after treatment?
Blood levels of soluble brain-derived proteins, including beta-amyloid 40, beta-amyloid 42 and GFAP, increased. MRI measurements also showed changes in fluid flow and around large brain veins.
Does the study show that the treatment prevents dementia?
No. The study involved 29 healthy adults and measured short-term biological and imaging changes. It did not test whether the treatment prevents dementia, slows disease or improves memory.
What is planned next?
The researchers say they are planning follow-up studies to examine possible benefits for people with early-stage memory impairment. The design and timing of those studies have not been reported.
Source: news-medical.net
